Wave Life Sciences, Inc.
corporate_fare Company Profile
Wave Life Sciences, Inc. (NASDAQ:WVE) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 24 items for WVE at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-27, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 10 rated 8 or above. Recent SEC coverage for WVE spans 10-Q, 8-K12B, 8-K, DEF 14A.
Recent high-impact activity:
- Wave Q3 Loss Widens to $61.9M; Cash Falls to $431.0M With No ATM Sales
- Wave Posts $61.9M Q3 Loss, Cash Runway to 3Q 2028, GSK Picks siRNA Candidate
- FDA Backs Registrational Path for Wave's RNA Editing Drug in AATD
- Wave Life Sciences Starts Phase 2a Trial of WVE-007 with Tirzepatide for Obesity
- Wave Life Sciences finalizes Delaware redomiciliation, new parent company assumes control
Financial Snapshot
Short Interest & Short Volume
6.76 days to coverFINRA reported short interest of 20,649,846 shares in WVE as of the October 30, 2026 settlement, a 2.4% decrease from the prior period — about 6.8 days to cover at its recent average daily volume. On November 19, 2026, 49.7% of WVE volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Moderate riskFiling-implied dilution signals for WVE, detected from its recent SEC filings.
Shelf Registration Adopted for New Delaware Parent · ATM Program Prospectus Updated
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →